ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TSTL Tristel Plc

480.00
15.00 (3.23%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  15.00 3.23% 480.00 460.00 480.00 470.00 465.00 465.00 33,518 16:35:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 36.01M 4.46M 0.0941 49.95 222.78M
Tristel Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker TSTL. The last closing price for Tristel was 465p. Over the last year, Tristel shares have traded in a share price range of 327.50p to 499.00p.

Tristel currently has 47,400,993 shares in issue. The market capitalisation of Tristel is £222.78 million. Tristel has a price to earnings ratio (PE ratio) of 49.95.

Tristel Share Discussion Threads

Showing 2451 to 2473 of 4000 messages
Chat Pages: Latest  100  99  98  97  96  95  94  93  92  91  90  89  Older
DateSubjectAuthorDiscuss
08/3/2016
18:49
So:

optimistically..... glass half full?

eeza
08/3/2016
17:47
This will break your pattern, Piedro, and transform you from a pessimist to an optimist...perhaps :-)
apad

apad
08/3/2016
16:47
"I would be more than happy if/when TSTL’s managers exercise these change-of-control options for a very fat profit."

Don't be fooled!!
A buyout would need to be with the approval of the board and usually works in the following manner ...
... 15% premium to the share price + board seats in the new company

It has happened to me 3 times - HMY, VDN and AND and not a very pleasant experience as so much research goes to waste.
In all 3 cases the Company was looking for a helping hand to leap into the future.

I also suspect that Mr. Soler + buddies would prefer marriage with a bigger company than getting in another 'Samler'.

AIMHO, BWDIK.

piedro
04/3/2016
16:56
Haven't been able to find any IC comment?
apad

apad
04/3/2016
11:28
I don't think he would be buying little chunks in dribs and drabs if he was intending to take the company private as his actions (plus the orchestrated director buying we saw a few days ago) has the effect of boosting the share price. He either sees the shares as cheap or he is trying to create a floor for the share price, I suspect a bit of both.
nehpets81
02/3/2016
18:57
As mentioned before I think that in view of the immense costs of USA market presence and FDA approval this company with its unique product offering would be best placed under the shelter of a bigger health care co. In which case it would make sense if as ceo you owned as much stock as possible. Obviously to comply with the law he cannot know of any likely bidder but when and if he does it will be too late to buy more stock. On the the other hand as Hyrus says he might just think they are cheap.
An agreed take out with a 40% premium to the last option vesting price would make a price of 187p. Just a fairy story for now.

bolador
02/3/2016
18:40
I think he believes it's cheap is all.
hydrus
02/3/2016
17:46
It's a bit volatile at the moment - today was good volatility ! (Didn't realise chairman owned so many)
davr0s
02/3/2016
17:13
...chairman again.

What's he up to? He already has more than a quarter of the company, if he keeps buying perhaps he intends to take it private??

Or, perhaps he just thinks cheap SP, so why not.

naos
02/3/2016
11:15
And another director buy.
pyglet
02/3/2016
01:03
juuunx2,

Is it not a dirty word?

piedro
01/3/2016
19:21
Piedro isn't that two words?
juuunx2
01/3/2016
14:12
I think one need's to focus on the EPS without share based payments going forward and I share the managements optimisim . The SBP's are a on off in this half. As the trigger point was 134p and alreday accrued I agree with PP there is scope back to 130p. Definitely a stong hold for the future prospects long term. Happy to go to sleep on this one.
zipstuck
01/3/2016
08:22
Piedro

Have you ever a good word to say for Tristel?

murray80
29/2/2016
22:13
"There's no doubt they have dropped a big clanger with a badly designed share options scheme"

... dropping 'clangers'
- could the MediChem deal be put in that class?
- they all seem good ideas at the time.

piedro
29/2/2016
21:05
Another update from Paul Scott (turning more positive)...

Regards,
Source.

+++++++++++++

Tristel (LON:TSTL)

Share price: 108.75p (up 4.6% today)
No. shares: 42.2m
Market cap: £45.9m

(at the time of writing, I hold a long position in this share)

Director purchases - I'm really not a fan of orchestrated Director share purchases after bad news, but as mentioned recently for another company, it does seem to work in some situations anyway, in helping to reassure investors. Perhaps it works in marginal situations, where confidence is beginning to return anyway, which is how I see Tristel?

I reported here on 24 Feb 2016 on Tristel's interim results, and the various factors which triggered a sharp correction in the share price. My view, when the shares were at 125p at the time of writing that report, was that the price looked "a bit too high", but that the "longer term upside still looks good".

The share price subsequently dropped considerably more, and went as low as the low-mid 90p's yesterday morning. At around that level, I think it was a reasonably good purchase, so I picked up a few, more of a dabble than a conviction buy.

Management webinar - I was also really impressed with the webinar that TSTL management did with Equity Development yesterday lunchtime. I watched/listened, and felt that management were open in addressing the criticisms of the slowing sales growth, and the share options charge. There's no doubt they have dropped a big clanger with a badly designed share options scheme, but I think they recognise that, and were emphatic that there would be no repetition in the next 3-5 years.

Various other factors mitigate my concerns over the slowing growth rate (now 8%), such as 4% being due to currency effects, and also that low margin products have been dropped - hitting turnover, but having little to no impact on profit.

Overall, I take my hat off to TSTL management for being so open with private investors, and not only holding a webinar, but also a meeting in London, open to private investors. Feedback from this has also been positive. This is outstanding stuff - if only all companies were so willing to engage with their PI shareholder base - especially when contentious issues arise.

TSTL is already being rewarded with a rebound in the share price. I think the glass is slowly turning from half empty, to half full again. The upside from potential US FDA approvals is something that I'd like to stick around for, as that could be a significant catalyst for future growth. I'm not sure there is necessarily much short term upside from here, but who knows? I would have thought it might recover to say 120-130p after a while.

source
29/2/2016
07:43
Another buy by the chairman. Big one this time. Regards,Source.
source
27/2/2016
16:51
As I predicted on results day Investors Chronicle rates as a buy for long term growth prospects
juuunx2
26/2/2016
15:56
That Chinese hospital looks amazing!Regards,Source.
source
26/2/2016
15:32
Piedro :-) it's the weekend
juuunx2
26/2/2016
15:01
juuunx2
"if you don't like the stock xxxxoff and moan somewhere else"

:-(

piedro
26/2/2016
15:00
juuunx2
"if you don't like the stock xxxxoff and moan somewhere else"

:-(

piedro
26/2/2016
15:00
juuunx2
"if you don't like the stock xxxxoff and moan somewhere else"

:-(

piedro
Chat Pages: Latest  100  99  98  97  96  95  94  93  92  91  90  89  Older

Your Recent History

Delayed Upgrade Clock